• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Bedaquiline efficacious in treating multidrug resistant tuberculosis: phase 2 trial

byAli ShahbazandXu Gao
August 21, 2014
in Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

1. After 24 weeks, patients who were given bedaquiline yielded a faster sputum culture conversion rate when compared to placebo. Both groups were given a five-drug, second-line antituberculosis background regimen. 

2. More deaths occurred in patients treated with bedaquiline compared to treatment with placebo. 

Evidence Rating Level: 1 (Excellent) 

Study Rundown: Although current antibiotic treatments have been successful in treating tuberculosis, the recent rise in multidrug resistant strains has proven to be a major challenge. Of the 8.6 million cases of tuberculosis in 2012, 450,000 were due to multidrug-resistant strains. In late 2012, for the first time in decades, a novel tuberculosis drug was approved by the FDA. This drug, called bedaquiline, works by inhibiting mycobacterial ATP synthase. Stage 1 of the TMC207-C208 phase 2b study found that the addition of bedaquiline to the preferred therapy for 8 weeks resulted in increased antibacterial activity.

In this stage 2 of the phase 2b trial, the authors further evaluated the efficacy and safety of bedaquiline with a longer treatment duration of 24 weeks. Results were consistent with that of the previous trial: the addition of bedaquiline to a conventional five-drug background regimen led to faster and more culture conversions at 120 weeks when compared to placebo plus the same background regimen. Notably, more deaths occurred in the group treated with bedaquiline as compared to placebo, although data was statistically insignificant.

While the results are promising, the study was limited by the small sample size, only 79 patients received bendaquiline. In addition, the study also excluded patient receiving antiretroviral therapy for HIV infection. The increased mortality rate with bendaquiline is also concerning.

Click to read the study, published today in NEJM

RELATED REPORTS

#VisualAbstract: Non-severe tuberculosis in children can be treated with a shorter 4-month regimen instead of 6-month regimen

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

Click to read the accompanying editorial in NEJM

Relevant Reading: Drug -resistant tuberculosis

In-Depth [randomized controlled trial]: This study recruited patients 18-65 years old who were recently diagnosed with pulmonary multidrug resistant tuberculosis. Trial sites were set up across 8 countries around the world. The patients were randomized to receive either bedaquiline or a placebo in addition to a five-drug, second-line anti-tuberculosis background regimen.

60 patients discontinued prematurely as a result of adverse events encountered or withdrawal of consent. The median time to sputum-culture conversion was faster in the bedaquiline compared to the placebo group of 2.44 (95% confidence interval [CI], 1.57 to 3.80, P< 0.0001). Additionally, it was supported that more patients in the bedaquiline group rather than the placebo group had confirmed culture conversion at both 24 and 120 weeks: 52 of 66 patients (79%) and 38 of 66 (58%) in the two groups, respectively, at 24 weeks (P= 0.008). In the bedaquiline group, 10 of 79 (13%) patients died as compared to 2 of 81 (2%) in the placebo group (P=0.02).

Image: PD

©2012-2014 2minutemedicine.com. All rights reserved. No works may be reproduced without expressed written consent from 2minutemedicine.com. Disclaimer: We present factual information directly from peer reviewed medical journals. No post should be construed as medical advice and is not intended as such by the authors, editors, staff or by 2minutemedicine.com. PLEASE SEE A HEALTHCARE PROVIDER IN YOUR AREA IF YOU SEEK MEDICAL ADVICE OF ANY SORT.

Tags: Bedaquilinetuberculosis
Previous Post

Active commuting associated with a lower BMI, body fat

Next Post

Lenalidomide may boost prognosis in diffuse large B-cell lymphoma

RelatedReports

#VisualAbstract: COVID-19 vaccines provided durable protection from COVID-19, but their effectiveness waned over time in North Carolina
StudyGraphics

#VisualAbstract: Non-severe tuberculosis in children can be treated with a shorter 4-month regimen instead of 6-month regimen

April 13, 2022
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Non-severe tuberculosis in children can be treated with a shorter 4-month regimen

March 16, 2022
#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis
StudyGraphics

#VisualAbstract: Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

May 18, 2021
Updated review confirms efficacy and safety of most standard treatments for latent tuberculosis infection
Chronic Disease

Rifapentine-moxifloxacin noninferior to standard of care treatment for pulmonary tuberculosis

May 10, 2021
Next Post
Mutation linked with decrease in cutaneous diffuse large B-cell lymphoma

Lenalidomide may boost prognosis in diffuse large B-cell lymphoma

Afatinib shows increased progression-free survival in non-small-cell lung cancer

New method may predict response to chemotherapy for lung cancer

Single course intravenous immunoglobulin ineffective at controlling severe solar urticaria

Single course intravenous immunoglobulin ineffective at controlling severe solar urticaria

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • LI-RADS outlines standards for liver imaging studies assessing HCC [Classics Series]
  • Daily disposable contact lenses may lower risk for Acanthamoeba keratitis
  • Vitamin D deficiency may be associated with sleep disorders in children
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.